Centessa Pharmaceuticals (CNTA) Long-Term Investments (2025 - 2026)
Centessa Pharmaceuticals (CNTA) reported Long-Term Investments of $257.1 million for Q1 2026, up 83.14% year-over-year from $140.4 million in Q1 2025, and down 9.0% on a QoQ basis from $282.5 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 2 years of Long-Term Investments data on file, last reported at $257.1 million in Q1 2026.
- Quarterly Long-Term Investments rose 83.14% year-over-year to $257.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $257.1 million (up 83.14% YoY) and the FY2025 annual result came in at $282.5 million, changed N/A from the prior year.
- Long-Term Investments retreated to $257.1 million in Q1 2026 per CNTA's latest filing, from $282.5 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $282.5 million in Q4 2025 and bottomed at $102.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | 257.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 257.12 Mn |
| Dec 31, 2025 | 282.55 Mn |
| Sep 30, 2025 | 102.83 Mn |
| Jun 30, 2025 | 153.41 Mn |
| Mar 31, 2025 | 140.40 Mn |